Navigation Links
Orexigen Resubmits Contrave New Drug Application
Date:12/11/2013

most frequent adverse events in patients on Contrave were nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. These were mostly mild to moderate in severity.

Orexigen has licensed North American Contrave rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and throughout the rest of the world outside of North America and will seek a partner to commercialize Contrave in those territories. In October 2013, Orexigen submitted a Marketing Authorization Application (MAA) for Contrave to the European Medicines Agency (EMA).

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company resubmitted the Contrave NDA to the FDA. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: the timing of potential approval of the NDA for Contrave in the U.S. and the MAA for Contrave by the European Medicines Agency (EMA); the benefit
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
4. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
5. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
6. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
7. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
8. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
9. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
10. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/27/2014)... July 27, 2014 /PRNewswire-iReach/ -- This is ... Global and Chinese Vardenafil (CAS 224785-90-4) industry. ... of Vardenafil (CAS 224785-90-4) including its classification, ... explores global and China,s top manufacturers of ... capacity, production value, cost, gross margin and ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... 28, 2014 The Wireline Services Market in ... Europe with analysis and forecast of revenue. The Wireline services ... billion in 2013 to $2.4 billion by 2019, at a ... the TOC of the Wireline Services Market in Europe report, ... also provides a glimpse of the segmentation in the European ...
(Date:7/28/2014)... 2014 (HealthDay News) -- People with higher levels of ... diabetes, a new study suggests. Unlike white fat, ... actually improves insulin sensitivity, blood sugar control and fat-burning ... obese people," Labros Sidossis, a professor of internal medicine ... of Texas Medical Branch at Galveston, said in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 In response ... Americans face today, BlogHer, The Center for American Progress ... “Make Life Work,” a campaign to raise awareness and ... across the U.S. The joint initiative was announced on ... Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, The Center for ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5
... ... , ... 2010 -- Blue Cross Blue Shield of Massachusetts, Inc. (BCBSMA) and Northeast Health ... Quality Contract (AQC). The agreement marks the first North Shore physician group to adopt ...
... drugs before surgery let even high-risk women opt for ... breast cancer patients estrogen-lowering drugs before surgery enhances their ... instead of a full mastectomy, new research suggests. , ... at 118 hospitals across the United States. It focused ...
... ... A new iPhone App from Thinklabs provides everyone from ... for learning or classifying patient heart sounds. iMurmur 2 includes digital ... follows the release of Stethoscope App by Thinklabs, a complete clinical ...
... ... assembly, you can effectively block up to 90% of the unwanted noise bleeding through a common ... live, play, sleep or work in peace and quiet! , ... (PRWEB) May 25, 2010 -- Isolating one room,s noise from the next through ...
... themselves, consider suicide, study finds , TUESDAY, May 25 ... rare but disabling psychiatric disorder known as olfactory reference ... horrible smells and, as a result, often isolate themselves ... a result of this false belief, and they appear ...
... the Cleveland Clinic finds that patients suffering from cirrhosis ... of developing hepatocellular carcinoma than those who develop cirrhosis ... this study appear in the June issue of ... of the American Association for the Study of Liver ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Breast Cancer Study Offers New Hope 2Health News:Hearing Everything in a Heartbeat - New Heart Murmur App 2Health News:Hearing Everything in a Heartbeat - New Heart Murmur App 3Health News:Share Your Walls, Not the Noise. Introducing dB-Bloc for Common Wall Sound Bleed 2Health News:Rare Disorder Has People Convinced They Smell Bad 2Health News:Rare Disorder Has People Convinced They Smell Bad 3Health News:New study confirms link between nonalcoholic steatohepatitis and liver cancer 2Health News:New study confirms link between nonalcoholic steatohepatitis and liver cancer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: